As gene-modified cell therapies advance toward broader clinical adoption, scalable and affordable lentiviral vector manufacturing has become a critical bottleneck. Traditional CDMO models struggle to support the highly iterative, resource-intensive optimization required for lentiviral vector development, resulting in long timelines, high costs, and limited accessibility. In Robust Lentiviral Manufacturing Platforms in the Age of Accessible Cell Therapy, Vector BioMed examines why platform-based manufacturing is essential to overcoming these challenges. The paper introduces the LENTIVERSE™ platform, a modular approach that combines fully characterized, CGMP-ready off-the-shelf vectors with collaborative, custom vector engineering for novel therapies. Through LaunchSuite and VectorCraft, Vector BioMed demonstrates how standardized processes and deep lentiviral expertise can dramatically improve yield, reduce cost of goods, and accelerate clinical timelines. Together, these strategies outline a practical path toward expanding global access to transformative cell and gene therapies.
Complete the form to download the full white paper and learn how platform-driven lentiviral manufacturing can accelerate development timelines, reduce costs, and expand access to transformative cell therapies.